Alantra advises STADA on the sale of branded asset FR!SKA to Megalabs
SECTORHealthcare
ServiceM&A
New York – Alantra, a leading global investment bank and asset management firm, is pleased to announce that it has advised STADA, a pan-European pharmaceutical company, on the Sale of US branded asset FR!SKA to Megalabs, a Uruguay-based multinational pharmaceutical manufacturing and distributing company.
FR!SKA is the only “Probiotics + Enzyme” two-in-one digestive brand on the market. The brand was founded and led by Target veteran, John Peine.
The Alantra US Healthcare team advising STADA included Rusty Ray, Christian Carlson, PhD, Michaela Zhang and Darius Kuddo.
Related Transactions
-
Apr 2025Sell-side advisoryApr 2025SECTOR HealthcareService M&A
-
Apr 2025Accelerated BookbuildingValue c. €42.4mnApr 2025SECTOR HealthcareService Equity Capital MarketsValue c. €42.4mn
-
Mar 2025Buy-side advisoryMar 2025SECTOR HealthcareService M&A
-
Dec 2024Corporate BrokerDec 2024SECTOR HealthcareService Corporate Broker; Equity Capital Markets